Veracyte, Inc. (VCYT)
POSITIVEFondamental
74
Prix
$42.84
Capitalisation boursière
$3.32B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$562M
12 derniers mois (au 30/06/2026)
Résultat net
$114M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$127M
Capitaux propres totaux
$1.31B
Passif total
$96M
Ratio de liquidité général
9.16
Couverture des intérêts
-
Dette/EBITDA
0.51
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$43.39
Prix actuel
$42.84
Marge de sécurité
+1.3%
Fourchette de juste valeur
$28.21 - $58.58
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
29.62
ROE
5.1%
Ratio P/B
2.40
P/FCF
20.08
Marge brute
71.7%
ROIC
5.9%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
5.9%
WACC
15.2%
ROIC − WACC
-9.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critères d'analyse fondamentale
Réussi (20)
- EPS shows upward trend
- Price CAGR 18.52%
- ROIC 5.9%
- Gross Margin 71.7%
- P/FCF 20.08
- P/B Ratio 2.40
- Debt/Equity ratio
- Operating Margin 18.8%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 8.6%
- Revenue Growth 5Y 34.5%
- Analyst Consensus 84% Buy
- Earnings Surprise avg 93.2%
- Earnings Quality (OCF/NI) 1.56
- Net Margin Trend 20.4% vs 5.5%
- Piotroski F-Score 8/9
Échoué (4)
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Share Dilution 3.9%
Indisponible (3)
- Dividend Payout NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Score F de Piotroski
Santé financière solide
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Émission de nouvelles actions, diluant la participation
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Marc A. Stapley | CEO & Director | 55 |
| Ms. Rebecca Chambers | Executive VP & CFO | 47 |
| Dr. Phillip G. Febbo M.D. | Chief Scientific & Medical Officer | 59 |
| Ms. Annie McGuire | Executive VP, General Counsel & Head of Market Access | 44 |
| Dr. John Leite Ph.D. | Global Chief Commercial Officer | 53 |
| Dr. Keith Gligorich Ph.D. | Senior Vice President of Global Operations | - |
| Mr. Jonathan Wygant | VP & Chief Accounting Officer | 54 |
| Dr. Kevin Richard Haas Ph.D. | Chief Development and Technology Officer | 40 |
| Mr. Steven French | Senior VP & Chief Information Officer | - |
| Ms. Kelly Gura | Director of Investor Relations | - |
Risque d'audit
2
Risque du conseil
2
Risque de rémunération
5
Risque droits des actionnaires
4
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for VCYT, sourced from Markets Gazette.
- 2/25/2026NEUTRALVeracyte (VCYT) Q4 2025 Earnings Call Transcript
Investors are keenly awaiting the transcript of Veracyte Inc.'s (VCYT) Q4 2025 earnings call, scheduled for February 25, 2026. While the announcement of such an event is standard for publicly traded companies, the current unavailability of the actual transcript content prevents any in-depth analysis of the financial data, future outlook, or strategic decisions discussed. The eventual release of these details will be crucial for understanding the company's performance and projections, potentially influencing market sentiment and investment decisions. Without this information, the market remains in a holding pattern, awaiting further clarity.
via Markets Gazette